Close Menu

LevitasBio: Paul Steinberg and Joseph Walthers

Jan 14, 2021

LevitasBio, a Stanford University spinout, has appointed Paul Steinberg as chief commercial officer and Joseph Walthers as VP of finance.

Steinberg will lead LevitasBio's commercial roadmap and strategy and manage commercial functions at the firm. He was most recently VP of worldwide sales at NanoString Technologies and has held leadership roles in commercialization and business development at Fluidigm and Thermo Fisher Scientific, respectively. He holds a master's degree in analytical chemistry from the University of Miami.

Walthers will be responsible for financial planning, budgeting, accounting, risk management, and internal controls activities. He has over 20 years experience at life science and biotech companies including Twist Bioscience, Natera, and Rainin Instrument. He is a licensed CPA in California.

More Like This

Jan 15, 2021

Broad Institute: Eric Lander, Todd Golub

Eric Lander, founding director of the Broad Institute of the Massachusetts Institute of Technology and Harvard, has been named White House science advisor to President-elect Joseph Biden. He will specifically be nominated as director of the Office of Science and Technology Policy and serve as Presidential Science Advisor. The President-elect is designating the Presidential Science Advisor as a member of the Cabinet for the first time in history. Lander was a principal leader of the Human Genome Project, and during the Obama Administration he served as external co-chair of the President's Council of Advisors on Science and Technology.

Lander will step down from his roles at Broad, Harvard, and MIT and take an unpaid, academic leave of absence.

The Broad Institute's board has appointed Todd Golub, current chief scientific officer at the institute, as director. Golub is a founder and core member of the institute, and serves on its executive leadership team. He is also the Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute and professor of pediatrics at Harvard Medical School. Golub joined the Dana-Farber and Harvard faculty in 1997, and served as a key scientific leader of the Whitehead Institute/MIT Center for Genome Research, the precursor organization of the Broad Institute. He has also been Howard Hughes Medical Institute investigator, and has served as chair of numerous scientific advisory boards, including St. Jude Children's Research Hospital and the National Cancer Institute's scientific advisory board.

Jan 15, 2021

Agilent Technologies: Allison Ballmer

Agilent Technologies has named Allison Ballmer as senior vice president of strategy and corporate development, reporting to President and CEO Mike McMullen.

Ballmer joined Agilent in May 2018 as vice president of business development and strategy for the company's Diagnostics and Genomics business. Prior to that, she worked for more than a decade at Roche. She is currently lead director of the board of directors at Mission Bio.

Jan 15, 2021

Exact Sciences: Andrew Slavitt

In a filing with the US Securities and Exchange Commission, Exact Sciences said that Andrew Slavitt submitted his resignation as a member of the company's board on Jan. 11 after having been been appointed by President-elect Joseph Biden as a White House Senior Advisor for COVID Response. 

Jan 14, 2021

Congenica Patient Advocacy and Engagement Advisory Board

Congenica has created a patient advocacy and engagement advocacy board and named Alastair Kent, former executive director of Genetic Alliance UK, as chair. Other members of the new board are:

  • Cor Oosterwijk, executive director of VSOP, the national patient alliance for rare and genetic diseases in the Netherlands;
  • Nicola Bedlington, former secretary general of and current special advisor to the European Patients' Forum; 
  • Lynsey Chediak, the World Economic Forum's project lead on precision medicine and rare diseases;
  • Luke Rosen, cofounder of rare disease advocacy group KIF1A.org; and
  • Malisa Rust, associate director of patient engagement at PTC Therapeutics.
Jan 14, 2021

Sema4: William Oh

Sema4 has appointed William Oh to the position of chief medical science officer, where he will drive strategy, scientific collaborations, clinical development, and adoption of the firm's technology.

Oh comes to Sema4 from Mount Sinai Health System, where he was chief of hematology and medical oncology and the deputy director of the Tisch Cancer Institute at the Icahn School of Medicine. He will continue to see patients at Mount Sinai.

Oh holds an MD from the New York University School of Medicine.

Jan 13, 2021

C2i Genomics: Mark Oldroyd, Ravi Kandasamy, Alex Parker

C2i Genomics has appointed Mark Oldroyd as its chief business officer, Ravi Kandasamy as VP of research and development, and Alex Parker as a member of the firm's board of directors. 

Oldroyd previously served as senior VP at Tempus. Prior to Tempus, he was a senior director at Foundation Medicine.

Kandasamy most recently served as director of genomics at Bristol-Myers Squibb. In addition, he has previously served as manager of research and development in precision medicine at GlaxoSmithKline.

Parker currently serves as senior VP for clinical product strategy at Thrive Earlier Detection. Prior to Thrive, he spent more than seven years in leadership positions at Foundation Medicine. 

Jan 13, 2021

Nanoview Biosciences: David Hanlon

Nanoview has appointed David Hanlon as its VP of strategic collaborations. Hanlon most recently served as VP of strategic communications at Quanterix. He has also held leadership roles at several life sciences and diagnostic firms, including Hologic. 

Jan 08, 2021

Gen InCode: Bill Rhodes

Gen InCode, a privately owned UK-based company specializing in cardiovascular disease genetic risk assessment, has appointed Bill Rhodes as non-executive chairman. Rhodes has previously served as worldwide president of Becton Dickinson's Biosciences business and was BD's corporate executive officer for strategy and corporate development. Rhodes also currently serves as chairman at OpGen, Omega Diagnostics Group, and CytoSmart Technologies. He was formerly chairman of the Curetis supervisory board until that company's merger with OpGen.

Jan 08, 2021

Qiagen: Toraf Haag

Qiagen said Toraf Haag has been appointed to its supervisory board and audit committee. Since 2018 Haag has served as chairman of the management board of Germany-based global technology firm Voith. Before joining Voth in 2016 as chief financial officer, Haag served for more than 11 years as CFO and an executive committee member at Lonza Group.

Jan 08, 2021

Pacific Biosciences: Mark Van Oene, Peter Fromen

Pacific Biosciences announced it has appointed Mark Van Oene to the newly created role of chief operating officer and Peter Fromen as chief commercial officer (CCO), both effective Jan. 8, 2021.

Van Oene joins PacBio after 15 years at Illumina, where he most recently served as senior VP and CCO and oversaw worldwide sales and service. He will be responsible for managing PacBio's research, development, and manufacturing organizations and for driving strategic planning and corporate development activities.

Fromen also joins from Illumina, where he most recently served as global VP of population genomics and precision health. Based in London since 2015, he oversaw Illumina's partnership with Genomics England and the National Health System. Fromen will be responsible for all commercial activity worldwide, including sales, marketing, and customer support.

Jan 06, 2021

DermTech: Ray Akhavan

DermTech has appointed Ray Akhavan as its general counsel. Most recently, Akhavan served as associate general counsel and chief intellectual property counsel at Ancestry. Prior to Ancestry, Akhavan served as general counsel and chief intellectual property counsel at Caris Life Sciences. He has also worked as a research biologist at the National Institutes of Health and as a patent examiner at the US Patent and Trademark Office. 

Jan 06, 2021

TwinStrand Biosciences: Gary Gilliland

Gary Gilliland has been appointed to the board of directors of Seattle-based TwinStrand Biosciences. Until February 2020, he was the president and director of the Fred Hutchinson Cancer Research Center. Prior to that, he was a professor at Harvard Medical School, director of the leukemia program at the Dana-Farber Cancer Institute, senior VP and global oncology franchise head at Merck, and vice dean of the Perlman School of Medicine at the University of Pennsylvania. Gilliland holds an MD from the University of California, San Francisco, and a PhD in microbiology from the University of California, Los Angeles.

Jan 05, 2021

Novacyt: James McCarthy, Anthony Dyer

Clinical diagnostics firm Novacyt has appointed James McCarthy as its CFO and Anthony Dyer to a new role as its chief corporate development officer. McCarthy will become a board director, subject to shareholder approval at the company's annual general meeting. Dyer will remain a board director until then.

McCarthy has held senior positions in listed and private equity-backed businesses. He was CFO of Flint Group, and of Brambles' Europe, Middle East, and Africa-based Commonwealth Handling Equipment Pool (CHEP) business before being promoted to president of CHEP’s European team.

McCarthy trained as an accountant with Dairygold and has worked for Unilever and ICI, among other companies.

Jan 05, 2021

Nautilus Biotechnology: Subra Sankar, Anna Mowry, Chris Blessington

Proteomics platform developer Nautlius Biotechnology has appointed Subra Sankar as senior vice president of product development, Anna Mowry as vice president of finance and business operations, and Chris Blessington as vice president of corporate marketing and communications.

Sankar joins Nautilus from GenapSys, where he was senior vice president of product development. He has also served in senior roles at Solexa and Illumina. Mowry most recently served as vice president of finance and operations at Igneous. She also previously held a variety of roles at Amazon Web Services and Isilon Systems. Blessington joins Nautilus from Smartsheet, where he held the role of vice president of marketing and communications. Prior to that he led marketing and communication teams at ExtraHop Networks, Isilon Systems, and EMC (which acquired Isilon).

Jan 05, 2021

Biodesix: Ryan Siurek

Ryan Siurek has joined Biodesix as chief accounting officer. He was previously SVP, chief accounting officer and controller of Vail Resorts. Prior to that, he held various accounting and finance roles at Sprint, including VP controller and chief accounting officer, and VP, divisional CFO for the prepaid and wholesale and enterprise solutions divisions.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.